Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab Maintenance Therapy for Active Non-infectious Intermediate, Posterior, or Pan-uveitis Requiring High-dose Corticosteroids
jRCT2080221170Phase 3
- Sponsor
- AbbVie Inc.
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-infectious intermediate uveitis, Posterior uveitis (non-infectious) and non-infectious panuveitis (NIU) comparing Adalimumab arm with Placebo arm (2 arms).
02
Drugs
03
Conditions
non-infectious intermediate uveitisPosterior uveitis (non-infectious)non-infectious panuveitis (NIU)
Beyond the preview
Go deeper on jRCT2080221170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221170.